Envisagenics
Envisagenics is a biotechnology company that leverages its AI platform, SpliceCore®, to discover novel drug targets and develop breakthrough treatments for diseases, particularly in oncology and neurodegeneration. Their approach combines deep expertise in RNA biology and artificial intelligence to identify high-impact, novel therapeutic targets by harnessing the potential of RNA splicing. Envisagenics aims to deliver safer and more effective therapies for conditions with urgent unmet needs by focusing on disease-specific splicing events that are also common across patients. The company has a validated pipeline of drug targets and therapeutics, including specific assets like ENV-375 and ENV-378 for CNS indications, and targets in breast cancer, lung cancer, and AML. They have secured significant funding and strategic partnerships with major pharmaceutical companies like Johnson & Johnson and Bristol Myers Squibb.
Envisagenics
Envisagenics is a biotechnology company that leverages its AI platform, SpliceCore®, to discover novel drug targets and develop breakthrough treatments for diseases, particularly in oncology and neurodegeneration. Their approach combines deep expertise in RNA biology and artificial intelligence to identify high-impact, novel therapeutic targets by harnessing the potential of RNA splicing. Envisagenics aims to deliver safer and more effective therapies for conditions with urgent unmet needs by focusing on disease-specific splicing events that are also common across patients. The company has a validated pipeline of drug targets and therapeutics, including specific assets like ENV-375 and ENV-378 for CNS indications, and targets in breast cancer, lung cancer, and AML. They have secured significant funding and strategic partnerships with major pharmaceutical companies like Johnson & Johnson and Bristol Myers Squibb.